Navigation Links
Proton beam therapy shows encouraging long-term outcome for patients with locally advanced sinonasal cancers

Proton beam radiation therapy shows encouraging results for patients with locally advanced sinonasal malignancies, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

Sinonasal cancers are very rare but aggressive types of cancer. Patients usually present with advanced stage with tumors involving normal structures in the skull base such as eyes, optic nerves, brain. Between 1991 and 2003, 99 patients with newly diagnosed sinonasal cancers were treated with proton beam therapy at Massachusetts General Hospital in Boston. Sixty-seven percent of the patients had some type of surgery prior to their radiation. The median total dose to the primary tumor was 70 Gray. After a median follow-up of 8.5 years, the local control rates at five and eight years were 87 percent and 83 percent, respectively, and there was no statistically significant difference in local control per histological subtype, T stage, and surgery vs. biopsy.

"Due to the anatomical location of sinonasal cancers, conventional radiation therapy results in very poor local control and is associated with significant treatment-related toxicity," Annie Chan, M.D., a radiation oncologist and the principal investigator of the study at Massachusetts General Hospital, Harvard Medical School, said. "Proton beam radiation therapy, with its superior dose distribution, allows the delivery of higher doses of radiation to the tumor while sparing more or the healthy surrounding tissues. This study showed very encouraging results for these patients and now prospective multi-institutional studies are being planned to further study the use of proton therapy in the treatment of this rare but aggressive malignancy."


Contact: Beth Bukata
American Society for Radiation Oncology

Page: 1

Related medicine news :

1. Historic Agreement Reached to More Expertly and Efficiently Expand Proton Therapy Worldwide
2. Wyeth Receives FDA Approval of Protonix for Delayed-Release Oral Suspension
3. Loma Linda University to Dedicate Proton Treatment Center to Cancer Therapy Pioneer James M. Slater, M.D.
4. Eclipse(TM) Proton Scanning Algorithm from Varian Medical Systems Receives FDA Clearance
5. Proton-powered pooping
6. Wyeth Announces Launch of Own Generic Version of PROTONIX
7. Caraco Pharmaceutical Laboratories Ltd. to Market Generic Protonix(R)
8. Seattle Cancer Care Alliance and Northwest Hospital Sign Letter of Intent to Develop Proton Therapy Center for Cancer Treatment
9. Gastric juice for diagnosis of H. pylori infection in patients on proton pump inhibitors
10. Varian Medical Systems to Develop Interface Between the ARIA(TM) Oncology Information System and the Monarch250(TM) Proton Radiotherapy System From Still River Systems
11. LegalView Warns Proton Pump Inhibitor Patients of Potential Bone Fracture Risk Associated with Drug
Post Your Comments:
(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... According ... Vinci surgical robot is being more and more widely heralded as a breakthrough for ... da Vinci method has over traditional laparoscopic surgery is that it can greatly reduce ...
(Date:11/25/2015)... ... November 25, 2015 , ... The McHenry County law firm ... appellate decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys Botto ... Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, Adcock testified ...
(Date:11/25/2015)... ... November 25, 2015 , ... Brillianteen, McGaw ... and learning in its 65th Anniversary Brillianteen Revue, scheduled for March 4-6, 2016. ... For 65 years, Brillianteen has been a treasured tradition for numerous families in ...
(Date:11/25/2015)... ... November 25, 2015 , ... In ... nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care for pulmonary hypertension ... Pioneers, nominated by the public, will receive special recognition throughout 2016 as part ...
(Date:11/25/2015)... ... November 25, 2015 , ... Bcureful—a non-profit organization devoted ... as raising public awareness of the disorder while helping to bring expert medical ... $35,000 to bolster progress at the Tuberous Sclerosis Complex Center at Ann & ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: AMGN ... Application (BLA) with the United States ... 501, a biosimilar candidate to Humira ® (adalimumab). ... application submitted to the FDA and represents Amgen,s first ... Sean E. Harper , M.D., executive vice president of ...
(Date:11/25/2015)... 2015 On Tuesday, November 24, 2015, ... against Wright Medical Technology, Inc. for product liability ... hip implant device, awarded $11 million in favor ... trial and three days of deliberations, the jury ... defectively designed and unreasonably dangerous, and that Wright ...
(Date:11/25/2015)... Allergan plc (NYSE: AGN ) today announced that it ... State Attorney General,s Office to end the litigation ... with the Attorney General over the decision of Forest Laboratories, ... the now generic version of memantine immediate release tablets.  Under ... its counterclaims against New York , and ...
Breaking Medicine Technology: